Verrica Pharmaceuticals (DE:1NE0)
FRANKFURT:1NE0
1NE0 Stock Chart & Stats
€5.11
--
Market closed
€5.11
--
Day’s Range― - ―
52-Week Range€2.78 - €8.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€85.65M
Enterprise Value€33.58M
Total Cash (Recent Filing)€30.15M
Total Debt (Recent Filing)€1.63M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
May 12, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding17,178,785
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.58
Price to Sales (P/S)2.49
P/FCF Ratio-5.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.15Price Target Upside235.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.13
Revenue Forecast (FY)€22.91M
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressAdvancement of a late stage trial for a common warts treatment enhances the prospects for an additional approved indication and a larger addressable market.
Commercial Investment And LeadershipA financing round enabled investment in commercial operations, including hiring a chief commercial officer and plans for sales force optimization, which is expected to accelerate revenue scaling.
Market Adoption And Sales MomentumRecord monthly demand, improving sales volumes, expansion into higher prevalence territories, and an enhanced patient support hub point to rising prescribing and market share gains versus compounded alternatives.
Bears Say
Analyst Sentiment And RatingAnalyst maintains a Hold rating while awaiting more consistent sales growth, which may constrain investor conviction until adoption proves sustained.
Execution And Valuation RiskInvestment thesis depends on proving sustained adoption and execution, and potential additional indications are not reflected in the valuation, raising downside risk if execution falters.
Inconsistent Product SalesCore product sales remain inconsistent and have underperformed earlier launch expectations, creating uncertainty around near term revenue durability.
Verrica Pharmaceuticals News
1NE0 FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was €2.78 and its highest was €8.80 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is €85.65M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is May 12, 2026 which is in 32 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on Mar 11, 2026. The company reported -€0.487 earnings per share for the quarter, beating the consensus estimate of -€0.6 by €0.113.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.39.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 17,178,785 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -€0.487 in its last earnings report, beating expectations of -€0.6. Following the earnings report the stock price went up 2.101%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:1NE0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verrica Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€17.15 (235.57% Upside)
€17.15 (235.57% Upside)
Blogger Sentiment
Bullish
DE:1NE0 Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.44%
12-Months-Change
Fundamentals
Return on Equity
252.30%
Trailing 12-Months
Asset Growth
-12.99%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
1NE0 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in YCANTH dispensations, strategic partnerships, and positive regulatory feedback, offset by challenges like seasonality impacts and a lengthy EU filing process.View all DE:1NE0 earnings summaries1NE0 Stock 12 Month Forecast
Average Price Target
€17.15
▲(235.57% Upside)